Annals of Oncology 12:1711-1720, 2001
© 2001 European Society for Medical Oncology
research-article |
Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer
Royal Perth Hospital, Sir Charles Gairdner Hospital, University of Western Australia Australia
B. N. Gray, MD Cancer Research Institute Inc PO Box 405 Victoria Park WA 6979, Australia, E-mail bgray{at}strtex.com
Purpose: SIR-Spheres® are radioactive yttrium90 microspheres (SIR-Spheres®, Sirtex Medical Limited, Australia) used to selectively target high levels of ionising radiation to tumors within the liver. This trial was designed to measure any increased patient benefit by adding a single administration of SIR-Spheres to a regimen of regional hepatic artery chemotherapy (HAC) administered as a 12 day infusion of floxuridine and repeated at monthly intervals, vs. the same chemotherapy alone.
Patients and methods: A phase III randomised clinical trial entering 74 patients was undertaken on patients with bi-lobar non-resectable liver metastases from primary adenocarcinoma of the large bowel. Patient benefit criteria assessed in the trial were tumor response, time to disease progression in the liver, overall survival, quality of life, and treatment related toxicity. Tumor response was measured by serial changes in both cross-sectional tumor areas and total tumor volumes, provided any response lasted not less than three months as well as changes in serum carcino-embryonic antigen (CEA).
Results: The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44% vs. 17.6%, P = 0.01)
tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004).
The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06).
The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone. Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06). There was no increase in grade 3–4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
Conclusion: The combination of a single injection of SIR-Spheres® plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
cancer, chemotherapy, liver, SIR-Spheres®, SIRT, treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. A. van Hazel, N. Pavlakis, D. Goldstein, I. N. Olver, M. J. Tapner, D. Price, G. D. Bower, G. M. Briggs, M. A. Rossleigh, D. J. Taylor, et al. Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy J. Clin. Oncol., September 1, 2009; 27(25): 4089 - 4095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Kuebler Radioembolization of Liver Metastases in Patients With Colorectal Cancer: A Nonsurgical Treatment With Combined Modality Potential J. Clin. Oncol., September 1, 2009; 27(25): 4041 - 4042. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kennedy Intraarterial Yttrium-90 Microspheres for Hepatic Malignancies ASCO Educational Book, January 1, 2009; 2009(1): 251 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Sato, R. J. Lewandowski, M. F. Mulcahy, B. Atassi, R. K. Ryu, V. L. Gates, A. A. Nemcek Jr, O. Barakat, A. Benson III, R. Mandal, et al. Unresectable Chemorefractory Liver Metastases: Radioembolization with 90Y Microspheres--Safety, Efficacy, and Survival Radiology, May 1, 2008; 247(2): 507 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Atassi, A. K. Bangash, A. Bahrani, G. Pizzi, R. J. Lewandowski, R. K. Ryu, K. T. Sato, V. L. Gates, M. F. Mulcahy, L. Kulik, et al. Multimodality Imaging Following 90Y Radioembolization: A Comprehensive Review and Pictorial Essay RadioGraphics, January 1, 2008; 28(1): 81 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Kalva, A. Thabet, and S. Wicky Recent Advances in Transarterial Therapy of Primary and Secondary Liver Malignancies RadioGraphics, January 1, 2008; 28(1): 101 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gulec and J. A. Siegel Posttherapy Radiation Safety Considerations in Radiomicrosphere Treatment with 90Y-Microspheres J. Nucl. Med., December 1, 2007; 48(12): 2080 - 2086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gulec and Y. Fong Yttrium 90 Microsphere Selective Internal Radiation Treatment of Hepatic Colorectal Metastases Arch Surg, July 1, 2007; 142(7): 675 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Gulec and J. P. O'Leary A Tribute to a Nuclear Surgeon Arch Surg, July 1, 2007; 142(7): 683 - 684. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Sharma, G. A. Van Hazel, B. Morgan, D. P. Berry, K. Blanshard, D. Price, G. Bower, J. A. Shannon, P. Gibbs, and W. P. Steward Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy J. Clin. Oncol., March 20, 2007; 25(9): 1099 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Miller, A. L. Keppke, D. Reddy, J. Huang, J. Jin, M. F. Mulcahy, and R. Salem Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET Am. J. Roentgenol., March 1, 2007; 188(3): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Ryan Nonsurgical Approaches to Colorectal Cancer Oncologist, October 1, 2006; 11(9): 999 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Gulec, G. Mesoloras, and M. Stabin Dosimetric Techniques in 90Y-Microsphere Therapy of Liver Cancer: The MIRD Equations for Dose Calculations J. Nucl. Med., July 1, 2006; 47(7): 1209 - 1211. [Full Text] [PDF]
|
|
|
|
|
|
C. O. Wong, N. Pandit-Taskar, and S. M. Larson JNM Supplement on Molecular Radiotherapy J. Nucl. Med., October 1, 2005; 46(10): 1765 - 1766. [Full Text] [PDF]
|
|
|
|
|
|
R. Murthy, R. Nunez, J. Szklaruk, W. Erwin, D. C. Madoff, S. Gupta, K. Ahrar, M. J. Wallace, A. Cohen, D. M. Coldwell, et al. Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications RadioGraphics, October 1, 2005; 25(suppl_1): S41 - S55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rubin, C. Nutting, and B. Jones Metastatic Breast Cancer in a 54-Year-Old Woman: Integrative Treatment with Yttrium-90 Radioembolization Integr Cancer Ther, September 1, 2004; 3(3): 262 - 267. [Abstract] [PDF]
|
|